enGene Holdings is trading 5.23% down at $1.45, with biotech-sector weakness the strongest available context.
- XBI is down 2.39% during the regular session amid broad risk-off sentiment.
- No company-specific announcement dated November 2 explains the decline; the latest listed company press release is from October 13.
- Available search results do not independently verify the intraday cause.